Evaluating metabolic features in patients with liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess how metabolic features influence the FAST score in patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) in Egypt. Researchers will identify metabolic risk factors and evaluate their impact on stratifying MASLD patients based on predicted FAST scores. Participants will undergo a series of assessments including clinical examinations, laboratory tests, abdominal ultrasonography, and transient elastography to measure liver stiffness and controlled attenuation parameters. The study will calculate the NAFLD fibrosis score and FAST score to better understand liver health in these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients with MASLD who had steatosis detected by (VCTE-CAP) elastography

Exclusion Criteria:

* Patients with a history of significant alcohol consumption more than 30 g/day in men and \> 20 g/day in women.
* Patients with positive hepatitis B or C virus markers.
* Patients with autoimmune hepatitis.
* Patients with any other metabolic liver disease.
* Patients with hepatic focal lesions.

Where it's running

• Tanta University Hospitals
  Tanta, Gharbyea, Egypt Recruiting

Study contacts

• Study coordinator: Rania M Elkafoury, MD
• Email: rania.elkafoury@med.tanta.edu.eg
• Phone: +201004672358

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Health profile of MASLD in Kazakhstan and real-world use of Ursosan in Almaty

  This study tests how MASLD appears in adults in Kazakhstan and how Ursosan is used in real-world care for a subgroup in Almaty.

  Recruiting at 7 sites Kazakh Association of Internal Medicine Specialists · Aktobe, Aktobe and 6 other locations · NCT07889999

• Endohepatology-based reclassification of treatment indication in high-risk MASLD

  This study tests whether an endohepatology assessment can change treatment decisions for adults with high-risk MASLD.

  Recruiting University Hospital Muenster · Münster · NCT07877272

• ALN-CIDEB in adults with MASLD to see if it helps the liver

  This study tests whether ALN-CIDEB can help adults with MASLD and its liver damage compared to placebo.

  Recruiting at 4 sites Phase 3 Regeneron Pharmaceuticals · Miami, Florida and 3 other locations · NCT07854782

• Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity

  This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.

  Recruiting at 2 sites University of Palermo · Palermo, Palermo and 1 other locations · NCT07750535

• Taiwan green propolis for MASLD and lipid/metabolic issues

  This study tests whether Taiwan green propolis capsules can improve blood lipids and body fat in adults with MASLD compared to a placebo over 12 weeks.

  Recruiting Taipei Medical University · Dalin · NCT07692438

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.